インスリンのインド市場の評価：製品別、タイプ別、用途別、流通チャネル別、地域別、機会、予測（2019年度～2033年度）

インドのインスリンの市場規模は、2025年度の6億4,868万米ドルから2033年度に11億3,133万米ドルに達すると予測され、2026年度～2033年度の予測期間にCAGRで7.20%の成長が見込まれます。市場の成長は、糖尿病有病率の上昇、一般住民の意識の高まり、手頃な価格の治療を促進する政府の制度や政策の導入などによって後押しされています。世界保健機関（WHO）の推計によると、インドでは18歳以上の約7,700万人が糖尿病患者であり、約2,500万人が糖尿病予備軍です。

インドでは、座りがちな生活習慣の急速な普及、食生活の変化、都市化によって1型糖尿病と2型糖尿病の負担が増大しており、アナログ製剤やバイオシミラー製剤を含むさまざまなインスリン製品の需要も全国的に大きく伸びています。インドでは、特に若年層や中年層の診断率が上昇しており、インスリン治療の早期開始につながっています。したがって、インスリン治療はもはや進行期の糖尿病に限定されるものではなく、包括的な血糖管理の中心的な要素になりつつあります。製薬企業は、基礎インスリンとGLP-1アナログのような固定比率の複合製剤を開発し、包括的なソリューションを提供することで対応しています。糖尿病の負担は今後数年間で大幅に増大すると予測されており、市場は急速な成長と拡大が見込まれます。

当レポートでは、インドのインスリン市場について調査分析し、市場規模と予測、市場力学、主要企業の情勢などを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 米国関税の影響

第4章 エグゼクティブサマリー

第5章 インドのインスリン市場の見通し（2019年度～2033年度）

• 市場規模の分析と予測
  • 金額
• 市場シェアの分析と予測
  • 製品別
    • 速効型インスリン
    • 持効型インスリン
    • 複合インスリン
    • バイオシミラー
    • その他
  • タイプ別
    • ヒトインスリン
    • インスリンアナログ
  • 用途別
    • 1型糖尿病
    • 2型糖尿病
  • 流通チャネル別
    • 病院薬局
    • 小売薬局
    • オンライン薬局
  • 地域別
    • 北部
    • 東部
    • 西部・中部
    • 南部
  • 市場シェア分析：企業別（上位5社とその他 - 金額、2025年度）
• 市場マップ分析（2025年度）
  • 製品別
  • タイプ別
  • 用途別
  • 流通チャネル別
  • 地域別

第6章 需給分析

第7章 バリューチェーン分析

第8章 ポーターのファイブフォース分析

第9章 PESTLE分析

第10章 価格分析

第11章 市場力学

• 市場促進要因
• 市場の課題

第12章 市場動向と発展

第13章 規制枠組みとイノベーション

• 臨床試験
• 規制当局の承認

第14章 特許情勢

第15章 ケーススタディ

第16章 競合情勢

• マーケットリーダー上位5社の競合マトリクス
• 上位5社のSWOT分析
• 主要企業上位10社の情勢
  • Novo Nordisk India Private Limited
  • Biocon Limited
  • Eli Lilly and Company (India) Private Limited
  • Sanofi S.A.
  • F. Hoffmann-La Roche AG
  • Wockhardt Limited
  • Becton, Dickinson and Company (BD)
  • Takeda Pharmaceutical Company Limited
  • Pfizer Inc.
  • Boehringer Ingelheim India Private Limited

第17章 戦略的提言

第18章 調査会社について・免責事項

List of Tables

• Table 1. Competition Matrix of Top 5 Market Leaders
• Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. India Insulin Market, By Value, In USD Million, FY2019-FY2033F
• Figure 2. India Insulin Market Share (%), By Product, FY2019-FY2033F
• Figure 3. India Insulin Market Share (%), By Type, FY2019-FY2033F
• Figure 4. India Insulin Market Share (%), By Application, FY2019-FY2033F
• Figure 5. India Insulin Market Share (%), By Distribution Channel, FY2019-FY2033F
• Figure 6. India Insulin Market Share (%), By Region, FY2019-FY2033F
• Figure 7. By Product Map-Market Size (USD Million) & Growth Rate (%), FY2025
• Figure 8. By Type Map-Market Size (USD Million) & Growth Rate (%), FY2025
• Figure 9. By Application Map-Market Size (USD Million) & Growth Rate (%), FY2025
• Figure 10. By Distribution Channel Map-Market Size (USD Million) & Growth Rate (%), FY2025
• Figure 11. By Region Map-Market Size (USD Million) & Growth Rate (%), FY2025

India insulin market is projected to witness a CAGR of 7.20% during the forecast period FY2026-FY2033, growing from USD 648.68 million in FY2025 to USD 1131.33 million in FY2033. The market's growth is propelled by the rising prevalence of diabetes, increasing awareness among the general population, and the introduction of government schemes and policies to promote affordable treatments. The World Health Organization (WHO) estimates that approximately 77 million people over the age of 18 are living with diabetes and about 25 million people are prediabetic in India.

The growing burden of both type 1 and type 2 diabetes in India due to rapid adoption of sedentary lifestyles, changing dietary habits, and urbanization is also significantly driving the demand for various insulin products, including analog and biosimilar formulations across the country. The increasing rate of diagnosis in India, particularly among younger and middle-aged adults, is leading to earlier insulin initiation. Thus, insulin therapy is no longer limited to advanced-stage diabetes but is becoming a central component of comprehensive glycemic management. Pharmaceutical companies are responding by developing fixed-ratio combinations, such as basal insulin with GLP-1 analogs, to provide holistic solutions. With the burden of diabetes projected to grow significantly over the coming years, the market is expected to witness rapid growth and expansion.

New product Launches Boost Market's Growth

Both domestic and international companies are investing in research and development activities and regulatory approvals to meet the rising demand for diabetes management solutions in India. For instance, in October 2024, Wockhardt Limited submitted its fast-acting insulin analog, ASPARAPID, for regulatory approval to India's Drugs Controller General (DCGI). This indigenously developed insulin aspart injection will be available in prefilled disposable pens, cartridges, and vials, offering flexibility for diabetes management. Innovations and new product developments are expected to improve patient adherence, while fostering competition among the key players of the market, encouraging them to invest in research activities, further supporting the market's expansion.

Growing preference for Insulin Pens Drives Market Expansion

The demand for insulin pens is significantly increasing in India due to their ease of use, accurate dosing, and enhanced patient compliance, particularly among urban populations. Unlike traditional vials and syringes, pens reduce stigma and simplify administration, making them ideal for young adults and elderly patients alike. Domestic and international manufacturers are increasingly launching affordable reusable pens, which can be paired with biosimilar insulin cartridges to further lower treatment costs. Additionally, increasing awareness through diabetes camps and digital platforms is allowing patients to transition to these user-friendly drug delivery systems. For instance, in September 2022, Terumo India launched FineGlide, sterile pen needle for patients that require regular insulin injections. The product's availability both as a standalone item in pharmacies and bundled with major pharmaceutical brands expands its reach. As more patients and caregivers seek easy to use self-injection solutions, innovations such as FineGlide are expected to boost adherence to insulin therapy, thus fueling the growth and expansion of the market and improving diabetes care outcomes across the country.

Hospital Pharmacies Holds Major Market Share

Hospital pharmacies in India maintain higher insulin availability rates as compared to retail pharmacies due to their role in managing inpatient care and complex cases. They also hold different types of insulin, including analogue and human insulin, allowing them to support the diverse requirements of the patient population. Furthermore, hospital pharmacies are also benefits from government initiatives to improve diabetes management and an established healthcare infrastructure. The presence of knowledgeable professionals to guide the patient population and reliability and accessibility of these pharmacies is further supporting the segment's expansion. Additionally, leading hospital pharmacies across the country are also receiving recognition from different government organizations. For instance, in June 2024, Pharmacies of Shri Mahant Indresh Hospital received recognition from the Pharmacy Council of India (PCI) to impart training. Such approvals are expected to bolster the availability of training opportunities for pharmacy students across the country, allowing them to better serve the patients and support the segment's expansion.

Impact of the U.S. Tariff on India Insulin Market

Various pharmaceutical products have been exempted from the tariffs, allowing leading Indian manufacturers to continue exporting to the United States without the additional financial burden posed by tariffs.

However, introduction of tariffs on pharmaceutical products in the near future cannot be ruled out, forcing Indian manufacturers to invest in complex generics and biosimilars and focus on expanding in the emerging markets to reduce their reliance on the United States for revenue generation.

Indian manufacturers are expected to focus on self-reliance in key active pharmaceutical ingredients and self-reliance, allowing them to withstand the evolving trade policies and maintain their growth momentum.

Key Players Landscape and Outlook

The key players of the market are focusing on expanding their presence in the country. For instance, in March 2025, Eli Lilly and Company (India) Private Limited announced its plans to expand its insulin production business in India. The company's focus on advancing biomanufacturing and clinical trials aligns with India's Atmanirbhar Bharat initiative, aiming to boost domestic pharmaceutical production and reduce reliance on imports. Additionally, the launch of new therapies like Mounjaro (tirzepatide) addresses both diabetes and obesity, meeting the country's rising demand for advanced treatments. Eli Lilly's collaborations with Indian companies are expected to enhance distribution networks and local manufacturing, ensuring more widespread access to essential diabetes medications. Such efforts are expected to support the market's growth by fostering innovation and making insulin therapies more accessible and affordable for the patient population.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of the U.S. Tariffs

4. Executive Summary

5. India Insulin Market Outlook, FY2019-FY2033F

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Product
    • 5.2.1.1. Rapid-Acting Insulin
    • 5.2.1.2. Long-Acting Insulin
    • 5.2.1.3. Combination Insulin
    • 5.2.1.4. Biosimilar
    • 5.2.1.5. Others
  • 5.2.2. By Type
    • 5.2.2.1. Human Insulin
    • 5.2.2.2. Insulin Analog
  • 5.2.3. By Application
    • 5.2.3.1. Type 1 Diabetes Mellitus
    • 5.2.3.2. Type 2 Diabetes Mellitus
  • 5.2.4. By Distribution Channel
    • 5.2.4.1. Hospital Pharmacies
    • 5.2.4.2. Retail Pharmacies
    • 5.2.4.3. Online Pharmacies
  • 5.2.5. By Region
    • 5.2.5.1. North
    • 5.2.5.2. East
    • 5.2.5.3. West and Central
    • 5.2.5.4. South
  • 5.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, FY2025)
• 5.3. Market Map Analysis, FY2025
  • 5.3.1. By Product
  • 5.3.2. By Type
  • 5.3.3. By Application
  • 5.3.4. By Distribution Channel
  • 5.3.5. By Region

6. Demand Supply Analysis

7. Value Chain Analysis

8. Porter's Five Forces Analysis

9. PESTLE Analysis

10. Pricing Analysis

11. Market Dynamics

• 11.1. Market Drivers
• 11.2. Market Challenges

12. Market Trends and Developments

13. Regulatory Framework and Innovation

• 13.1. Clinical Trials
• 13.2. Regulatory Approvals

14. Patent Landscape

15. Case Studies

16. Competitive Landscape

• 16.1. Competition Matrix of Top 5 Market Leaders
• 16.2. SWOT Analysis for Top 5 Players
• 16.3. Key Players Landscape for Top 10 Market Players
  • 16.3.1. Novo Nordisk India Private Limited
    • 16.3.1.1. Company Details
    • 16.3.1.2. Key Management Personnel
    • 16.3.1.3. Products and Services
    • 16.3.1.4. Financials (As Reported)
    • 16.3.1.5. Key Market Focus and Geographical Presence
    • 16.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 16.3.2. Biocon Limited
  • 16.3.3. Eli Lilly and Company (India) Private Limited
  • 16.3.4. Sanofi S.A.
  • 16.3.5. F. Hoffmann-La Roche AG
  • 16.3.6. Wockhardt Limited
  • 16.3.7. Becton, Dickinson and Company (BD)
  • 16.3.8. Takeda Pharmaceutical Company Limited
  • 16.3.9. Pfizer Inc.
  • 16.3.10. Boehringer Ingelheim India Private Limited

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

17. Strategic Recommendations

18. About Us and Disclaimer